InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (12 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
12
T+90 hit rate
100%
T+90 mean return
+17.3%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Kewalramani Reshma, Chairman & CEO. Director active across 3 companies, notably Vertex Pharmaceuticals INC / MA. Aggregated, 42 disclosures have been recorded. Split: 2 buys · 12 sells. Total volume traded: €46.4m. Activity tracked since 19 August 2021. The latest transaction was disclosed on 27 February 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Kewalramani Reshma
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations42 total
400 shares@ US$479.751.3% of flowCommon StockSEC:0000875320-26-000129:0
4,981 shares@ US$485.1116.7% of flowCommon StockSEC:0000875320-26-000114:0
16,326 shares0Common StockSEC:0000875320-26-000090:0
13,041 shares@ US$487.7643.7% of flowCommon StockSEC:0000875320-26-000070:0
8,297 shares@ US$468.4126.6% of flowCommon StockSEC:0000875320-26-000046:0
26,972 shares0Common StockSEC:0000875320-26-000018:0
4,290 shares@ US$389.08100.0% of flowCommon StockSEC:0000875320-25-000220:0
Canonical exit: 4 Nov 2025 (T+90)
14,079 shares@ US$479.617.6% of flowCommon StockSEC:0000875320-25-000131:0
9,386 shares@ US$483.285.1% of flowCommon StockSEC:0000875320-25-000111:0
6,553 shares@ US$463.463.4% of flowCommon StockSEC:0000875320-25-000089:0
19,015 shares0Common StockSEC:0000875320-25-000067:0
8,300 shares@ US$467.984.5% of flowCommon StockSEC:0000875320-25-000044:0
29,118 shares0Common StockSEC:0000875320-25-000018:0
15,198 shares@ US$515.008.6% of flowCommon StockSEC:0000875320-24-000225:0
15,202 shares@ US$505.008.4% of flowCommon StockSEC:0000875320-24-000195:0
15,202 shares@ US$497.008.2% of flowCommon StockSEC:0000875320-24-000187:0
105,263 sharesClass A Common StockSEC:0001127602-24-018713:0
1,565 shares@ US$187.530.3% of flowCommon StockSEC:0000875320-24-000160:0
15,202 shares@ US$447.007.4% of flowCommon StockSEC:0000875320-24-000156:0
9,386 shares@ US$431.794.4% of flowCommon StockSEC:0000875320-24-000105:0
9,359 shares@ US$424.014.4% of flowCommon StockSEC:0000875320-24-000074:0
8,255 shares@ US$422.743.8% of flowCommon StockSEC:0000875320-24-000051:0
14,516 shares0Common StockSEC:0000875320-24-000026:0
3,058 shares@ US$155.570.5% of flowCommon StockSEC:0000875320-23-000062:0
5,098 shares@ US$397.002.2% of flowCommon StockSEC:0000875320-23-000058:0
25 of 42 declarations
About Kewalramani Reshma
Kewalramani Reshma is Chairman and Chief Executive Officer and Director. She is associated with Vertex Pharmaceuticals INC / MA, VERTEX PHARMACEUTICALS INC / MA, and Ginkgo Bioworks Holdings, Inc. The record shows 42 filings in total, and across the recent sampled filings, from 2021-08-23 to 2026-03-03, buy amounts are EUR 2393245 and sell amounts are EUR 43983937. The most frequent transaction nature is Tax withholding.
